Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), sold 2,314 shares at $54.28 ($126K) on 2025-11-25, disclosed to the SEC on 2025-11-25.
Seasonal sale ($126k) by Chief R&D Officer — this insider has traded NKTR in November in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.28 | 1,157 | $63K | 50.0% |
| 2 | $54.28 | 1,157 | $63K | 50.0% |
| Total | $54.28 avg | 2,314 | $126K | 100% |
| Filing → |
| NKTR | SELL | 2026-06-17 | $336K | — | Filing → |
| NKTR | SELL | 2026-05-21 | $13K | — | Filing → |
| NKTR | SELL | 2026-02-20 | $13K | — | Filing → |